Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies.

Formerly @twoXAR

[Aria Pharmaceuticals @ariapharma]

Aria VP of Discovery @AaronCDaugherty shares his opinion on what to expect in #AI in #drugdiscovery in 2023 in the latest edition of @DrugTargetRev

[Drug Target Review @DrugTargetRev]

In this exclusive article, @AaronCDaugherty from @ariapharma highlights how the industry can use AI to transform research.
Read more here: https://t.co/vbWYpZTtlF
#bioinformatics #artificialintelligence #drugdiscovery #AI

[Aria Pharmaceuticals @ariapharma]

"The next wave of innovation in AI must examine how all the puzzle pieces of human biology are connected..." Aria SVP of R&D Mark G. Eller discussing technology as a new evolution of finding disease. https://t.co/afpS8O3rV2

[Aria Pharmaceuticals @ariapharma]

"That early exploration is the phase where disruptive technology can have a significant impact and bring more potential treatments to the clinic." Read more from Aria SVP of R&D Mark G. Eller discussing technology as the new evolution in fighting diseases.
https://t.co/prtrgQHePl

[Aria Pharmaceuticals @ariapharma]

"In 2022, Aria Pharmaceuticals made significant headway on nearly every front in our mission to bring novel and needed treatments into the clinic." Read more from CEO @andrew_radin as he reflects on Aria's progress in 2022.

https://t.co/KYBnFDORpE

[Aria Pharmaceuticals @ariapharma]

2022 was a year of progress for Aria. CEO @andrew_radin shared his thoughts on this year's accomplishments and looks ahead at 2023 and what's to come. https://t.co/KYBnFE5UrE

[Aria Pharmaceuticals @ariapharma]

We were pleased to have SVP of Nonclinical R&D and Chemistry Anjali Pandey present at the 6th Obesity & NASH Drug Development Summit where she presented on our latest data in #NASH. If you missed the presentation, you can now view it here: https://t.co/dEocs0Bvu8

[Aria Pharmaceuticals @ariapharma]

"I believe it is safe to say that with these traditional lab-based approaches, we have missed potential breakthroughs." Read more from VP Discovery @AaronCDaugherty on how a new approach could help us uncover new promising treatments in @DrugTargetRev
https://t.co/dLMAFQeHeP

[Aria Pharmaceuticals @ariapharma]

Using our Symphony™ AI-platform, @ariapharma has developed a robust pipeline of promising treatments across a range of complex diseases. Learn more about how Symphony™ is purpose-built for biological discovery: https://t.co/Iuehlept2A

[Rare Disease Advisor @RareDisease_Adv]

Promising results from the third preclinical study of TRX-1002, an #IdiopathicPulmonaryFibrosis (#IPF) treatment candidate, showed significant decrease in #AbsoluteLungWeight, #FibrosisScore, and collagen and hydroxyproline levels @ariapharma https://t.co/N7HolB9kTu #CureIPF

[Aria Pharmaceuticals @ariapharma]

Thanks to Pulmonary Fibrosis News for covering our latest findings in our IPF program! Here's a nice roundup of the data Anjali Pandey presented at the Antifibrotic Drug Development Summit in Boston.
https://t.co/ApkYDwrwDt

[Aria Pharmaceuticals @ariapharma]

The 6th Obesity & NASH Drug Development Summit kicks off tomorrow! Don't miss Aria SVP of Nonclinical R&D and Chemistry Anjali Pandey presenting on our latest findings in #NASH.

[Aria Pharmaceuticals @ariapharma]

Don't miss Aria SVP of Nonclinical R&D and Chemistry Anjali Pandey at the 6th Obesity and NASH Drug Development Summit next week where she'll be sharing the latest data from our #NASH program!

https://t.co/GCHMCxKT76

[Aria Pharmaceuticals @ariapharma]

We're please to announce the latest positive results from our IPF program presented at the AFDD Summit! This demonstrates another positive result for our lead TXR-1002 as we move closer to the clinic with a potential treatment for #IPF
https://t.co/velTDZbWLu

[Aria Pharmaceuticals @ariapharma]

We're excited to have SVP Nonclinical R&D and Chemistry Anjali Pandey presenting our latest results in #NASH and #IPF tomorrow at the Antifibrotic Drug Development Summit.

[Aria Pharmaceuticals @ariapharma]

This is biology's century - "Here’s what “biology’s century” means to me: In the same way the 20th century belonged to physics, the 21st is biological." A great piece from @matthewherper
https://t.co/GshFjqPr6y

[Aria Pharmaceuticals @ariapharma]

Following a recent @statnews article from @matthewherper discussing why we're not prepared for the next wave of innovation, our VP Discovery @AaronCDaugherty shared his thoughts on how a shift in mindset can facilitate better results in drug discovery: https://t.co/yR05ECUMaN

[Aria Pharmaceuticals @ariapharma]

It was an honor to have CEO @andrew_radin share the latest from Aria with the @mit_ilp in Seoul at the Startup Showcase and meet with other industry members!

[Aria Pharmaceuticals @ariapharma]

Join Aria SVP of Nonclinical R&D & Chemistry Anjali Pandey at the AFDD Summit Nov 9-11 where she'll be sharing the latest data from our #IPF program along with updates in #NASH. https://t.co/EPfU7UkOVD

[Aria Pharmaceuticals @ariapharma]

October is #healthylungmonth! Now is the perfect time to check on your lung health and follow these tips to help prevent lung-related illnesses!

[Aria Pharmaceuticals @ariapharma]

Utilizing Symphony™ @ariapharma has developed a pipeline of promising treatments in over a dozen programs across a range of therapeutic areas. Learn more about our pipeline here: https://t.co/dEocs0TEIg